RT Journal Article
SR Electronic
T1 Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.19.22271112
DO 10.1101/2022.02.19.22271112
A1 Stegger, Marc
A1 Edslev, Sofie Marie
A1 Sieber, Raphael Niklaus
A1 Cäcilia Ingham, Anna
A1 Ng, Kim Lee
A1 Tang, Man-Hung Eric
A1 Alexandersen, Soren
A1 Fonager, Jannik
A1 Legarth, Rebecca
A1 Utko, Magdalena
A1 Wilkowski, Bartlomiej
A1 Gunalan, Vithiagaran
A1 Bennedbæk, Marc
A1 Byberg-Grauholm, Jonas
A1 Møller, Camilla Holten
A1 Christiansen, Lasse Engbo
A1 Svarrer, Christina Wiid
A1 Ellegaard, Kirsten
A1 Baig, Sharmin
A1 Johannesen, Thor Bech
A1 Espenhain, Laura
A1 Skov, Robert
A1 Cohen, Arieh Sierra
A1 Larsen, Nicolai Balle
A1 Sørensen, Karina Meden
A1 White, Emily Dibba
A1 Lillebaek, Troels
A1 Ullum, Henrik
A1 Krause, Tyra Grove
A1 Fomsgaard, Anders
A1 Ethelberg, Steen
A1 Rasmussen, Morten
YR 2022
UL http://medrxiv.org/content/early/2022/02/21/2022.02.19.22271112.abstract
AB The newly found Omicron SARS-CoV-2 variant of concern has rapidly spread worldwide. Omicron carries numerous mutations in key regions and is associated with increased transmissibility and immune escape. The variant has recently been divided into four subvariants with substantial genomic differences, in particular between Omicron BA.1 and BA.2. With the surge of Omicron subvariants BA.1 and BA.2, a large number of reinfections from earlier cases has been observed, raising the question of whether BA.2 specifically can escape the natural immunity acquired shortly after a BA.1 infection.To investigate this, we selected a subset of samples from more than 1,8 million cases of infections in the period from November 22, 2021, until February 11, 2022. Here, individuals with two positive samples, more than 20 and less than 60 days apart, were selected. From a total of 187 reinfection cases, we identified 47 instances of BA.2 reinfections shortly after a BA.1 infection, mostly in young unvaccinated individuals with mild disease not resulting in hospitalization or death.In conclusion, we provide evidence that Omicron BA.2 reinfections do occur shortly after BA.1 infections but are rare.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted using data from the Danish COVID-19 surveillance. According to Danish law, ethics approval is not needed for this type of research but approved by the Legal Advisory Board at Statens Serum Institut, a Danish sector research institute under the auspices of the Danish Ministry of Health. The publication only contains aggregated results without personal data. Therefore, the publication is in compliance with the European General Data Protection Regulations.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available for research upon reasonable request to the Danish Health Data Authority and Statens Serum Institut and within the framework of the Danish data protection legislation and any required permission from authorities. Consensus genome data from the Danish cases are routinely shared publicly at GISAID (www.gisaid.org), including information on reinfections.